Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

The high failure rate in drug development is analogous to trying to repair a car with no mechanical knowledge—it's just "banging on different parts." This highlights the industry's need to shift from observing correlations to understanding the fundamental biological mechanisms of disease.

Contrary to belief that TKIs mainly worsen pre-existing issues, Nilotinib's cardiovascular toxicity can develop years into therapy, even in young patients without traditional risk factors. This implies a direct, long-term drug effect beyond just exacerbating comorbidities.

Novartis's cardio drug failure in a secondary prevention trial highlights a critical development challenge: even for genetically-validated targets, intervening late in a chronic disease's progression may be ineffective. The damage may already be too extensive, suggesting earlier treatment is needed to show a benefit.

Novartis's Lp(a) drug may have failed not because the target is wrong, but because patients were already so well-treated with existing drugs like statins. This highlights a growing challenge: new therapies must demonstrate significant added value over an increasingly effective standard of care.

The surprising failures of Novartis's and Novo Nordisk's heart drugs, both targeting 'genetically validated' pathways, have debunked the widely held belief that genetic data guarantees clinical success. This forces a fundamental rethink of using genetics to de-risk massive drug development investments.

The fastest, cheapest path to drug approval involves showing a small survival benefit in terminally ill patients. This economic reality disincentivizes the longer, more complex trials required for early-stage treatments that could offer a cure.

The primary hurdle in drug development is the Phase 2 trial, where the most frequent cause of failure is a simple lack of efficacy. It is not typically due to safety concerns, business case changes, or target engagement issues, but rather that the drug produces no therapeutic effect upon administration.

Chronic illnesses like cancer, heart disease, and Alzheimer's typically develop over two decades before symptoms appear. This long "runway" is a massive, underutilized opportunity to identify high-risk individuals and intervene, yet medicine typically focuses on treatment only after a disease is established.